Literature DB >> 1672971

Biotype as determinant of natural immunising effect of cholera.

J D Clemens1, F van Loon, D A Sack, M R Rao, F Ahmed, J ChakrabortY, B A Kay, M R Khan, M D Yunus, J R Harris.   

Abstract

To test the hypothesis that clinical Vibrio cholerae O1 infections protect against recurrent cholera, treated cholera episodes in a rural Bangladesh population of 188,153 people who were followed between 1985 and 1988 were analysed. Of the 2214 people with initial episodes of cholera, 7 had a second episode. The incidence of cholera was 61% lower in subjects who had had an earlier episode than in those without such an episode. Whereas initial episodes of classical cholera were associated with complete protection against subsequent cholera, initial episodes of El Tor cholera were associated with negligible protection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672971     DOI: 10.1016/0140-6736(91)90207-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Cholera in the Americas: an overview.

Authors:  J Sepulveda; H Gomez-Dantes; M Bronfman
Journal:  Infection       Date:  1992 Sep-Oct       Impact factor: 3.553

Review 3.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

4.  Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Authors:  D N Taylor; C O Tacket; G Losonsky; O Castro; J Gutierrez; R Meza; J P Nataro; J B Kaper; S S Wasserman; R Edelman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

5.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 6.  Killed oral cholera vaccines: history, development and implementation challenges.

Authors:  Anna Lena Lopez; Maria Liza Antoinette Gonzales; Josephine G Aldaba; G Balakrish Nair
Journal:  Ther Adv Vaccines       Date:  2014-09

7.  Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.

Authors:  Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

8.  Corresponding type-specificity of vibriocidal and agglutinating activities of Vibrio cholerae antisera: relevance to vaccine immunogenicity.

Authors:  N W Preston
Journal:  Epidemiol Infect       Date:  1993-06       Impact factor: 2.451

9.  CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain.

Authors:  J Michalski; J E Galen; A Fasano; J B Kaper
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1.

Authors:  Ashraful I Khan; Fahima Chowdhury; Jason B Harris; Regina C Larocque; Abu S G Faruque; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri
Journal:  Scand J Infect Dis       Date:  2010
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.